Figure 1.

Nobiletin inhibits agonist-induced platelet activation. Human-washed platelet aggregation performed in the presence or absence of various concentrations of nobiletin was monitored for 5 min by optical aggregometry following stimulation with 1 μg·mL⁻¹ (A and B) and 5 μg·mL⁻¹ collagen (C and D), 0.5 μg·mL⁻¹ (E and F) and 1 μg·mL⁻¹ CRP-XL (G and H) and 0.1 U·mL⁻¹ thrombin (I and J). Similarly, the effects of nobiletin on PRP were analysed following stimulation with 1 μg·mL⁻¹ collagen (K and L). Indomethacin (10 μM)-treated platelets were stimulated with 0.5 μg·mL⁻¹ CRP-XL in the presence and absence of nobiletin (M and N). Whole blood aggregation was performed using 10 μg·mL⁻¹ collagen in the presence and absence of nobiletin by impedance aggregometry (O and P). Cumulative data represent mean values ± SD (n = 3), the level of aggregation obtained at 5 min with vehicle-treated samples (0 μM) was taken as 100%. The P-values shown in the figure are calculated by non-parametric repeated measures anova (Friedman test; ****P < 0.0001).